Since the patent for Stelara (ustekinumab) expired in 2024, there are now four ustekinumab biosimilars available in the UK:
- Pyzchiva
- Steqeyma
- Uzpruvo
- Wenzela
We expect that the majority of the patients on BADBIR who are currently taking Stelara will switch to one of the biosimilars or may have already switched. When you are completing a follow-up for one of these patients, please double check that the correct ustekinumab brand is recorded.
If the patient has switched, you can enter a stop date for Stelara based on their last dose with the stop reason “Financial consideration” and then enter the new biosimilar with a start date matching their first dose. If you don’t know the exact dates, it’s fine to estimate. If you have any questions feel free to get in touch.